Denali Therapeutics (DNLI) Long-Term Investments (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Long-Term Investments data on file, last reported at $63.8 million in Q1 2026.

• On a quarterly basis, Long-Term Investments fell 72.95% year-over-year to $63.8 million in Q1 2026; TTM through Mar 2026 was $63.8 million, a 72.95% decrease from a year earlier, with the FY2025 full-year figure at $98.3 million, down 72.64% from the prior year.
• Long-Term Investments for Q1 2026 stood at $63.8 million, down from $98.3 million in the prior quarter.
• Over the last five years, Long-Term Investments for DNLI reached as high as $490.7 million in Q1 2024 and fell as low as $7.9 million in Q3 2023.
• Historically, Long-Term Investments has averaged $216.7 million across 5 years, with a median of $167.1 million in 2025.
• Across the five-year window, Long-Term Investments surged 5535.21% in 2024 and slumped 94.45% in 2025, its largest moves.
• Year by year, Long-Term Investments stood at $94.2 million in 2022, then sank by 91.61% to $7.9 million in 2023, then soared by 4446.15% to $359.4 million in 2024, then slumped by 72.64% to $98.3 million in 2025, then tumbled by 35.13% to $63.8 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $63.8 million in Q1 2026, $98.3 million in Q4 2025, and $24.7 million in Q3 2025.